4-[N'-(2,4,6-Trioxo-tetrahydro-pyrimidin-5-ylidene)-hydrazino]-benzoic acid methyl ester | 19849-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[N'-(2,4,6-Trioxo-tetrahydro-pyrimidin-5-ylidene)-hydrazino]-benzoic acid methyl ester
• 英文别名: methyl 4-[2-(2,4,6-trioxo-1,3-diazinan-5-ylidene)hydrazinyl]benzoate
• CAS: 19849-64-0
• 化学式: C₁₂H₁₀N₄O₅
• mdl: MFCD00746506
• 分子量: 290.235
• InChiKey: ZSKREZJJCSQRKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  巴比妥酸 、 4-氨基苯甲酸甲酯 在 盐酸 、 sodium nitrite 、 sodium acetate 作用下， 以 水 、 乙醇 为溶剂， 生成 4-[N'-(2,4,6-Trioxo-tetrahydro-pyrimidin-5-ylidene)-hydrazino]-benzoic acid methyl ester
  参考文献：
  名称：

  Synthesis, activity evaluation, and docking analysis of barbituric acid aryl hydrazone derivatives as RSK2 inhibitors

  摘要：

  The 90 kDa ribosomal S6 kinases (RSKs), especially RSK2, have attracted attention for the development of new anticancer agents. Through structural optimization of the hit compound 1 from our previous study, a series of barbituric acid aryl hydrazone analogues were designed and synthesized as potential RSK2 inhibitors. The most potent one, compound 9, showed a higher activity against RSK2 with an IC50 value of 1.95 mu M. To analyze and elucidate their structure-activity relationship, the homology model of RSK2 N-terminal kinase domain was built and molecular docking simulations were performed, which provide helpful clues to design new inhibitors with desired activities.

  DOI：

  10.3109/14756366.2012.681651